Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
Objective: We aimed to investigate the frequency of Janus kinase 2 ( JAK2) mutations in cases with chronic myeloproliferative disorders (CMDs), and the relationship between the presence of JAK2 mutation and leukocytosis and splenomegaly, retrospectively. Materials and Methods: Patients, who were dia...
Guardado en:
Autores principales: | Ismail Yildiz, Osman Yokuş, Habip Gedik |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a157274e74a74057940a257df7922f66 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Miguel Nogueira, et al.
Publicado: (2021) -
Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Magdalena M. Brune, et al.
Publicado: (2021) -
FREQUENCY OF TET2 GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
por: Syed Owais Ali, et al.
Publicado: (2021) -
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Jin-Woo Kim, et al.
Publicado: (2021) -
Molecular basis of essential thrombocythaemia in humans and dogs – a review
por: Nicola Padzik, et al.
Publicado: (2021)